Palantir at a Critical Turning Point – Big Moves on the HorizonAlright, here’s the deal with PLTR. I’ve been keeping a close eye on it, and right now, it feels like we’re standing at a fork in the trail—one direction leads to a nice payday, the other to a bit of backtracking. The next couple of moves will tell us which way we’re headed.
We’re hovering around 42.75 right now, and if we can break above that with some force, 43.91 is my first target—good spot to lock in some profits. But here’s the thing: if we can clear 44, that’s where the real fun begins. That’s the confirmation we’re looking for, and from there, I think this could open up a much bigger move.
On the other hand, if 41.65 doesn’t hold, things could get a bit rocky. I’ll be looking for price to drift down into the 41.28 - 41.00 range. Not ideal, but hey, markets don’t move in straight lines. That’s where I’ll watch for buyers to step back in and give us another shot at the upside.
The key here is patience. If we get the breakout, I’m ready to ride the wave. If we pull back, no sweat—I’m not in the business of chasing trades. You gotta play this game cool, stick to the levels, and wait for the setup to come to you. No need to rush it.
It’s kind of like hiking. Sometimes the first path up the hill looks tempting, but the trail turns steep, and you gotta fall back to find a better route. But when you do find that clean path—man, the view is worth the wait. That’s exactly what this trade feels like. If we clear 44, we’ve got some clear skies ahead, and I’ll be ready for the ride. But if not, I’m content to step back and wait for the next chance to make my move.
Let’s see where this takes us—either way, it’s gonna be an interesting climb.
Mindbloome trader
Palatintechnologies
Palatin Technologies 500%+ Expected ReturnCompany Profile
Sector: Health Care
Industry: Biotechnology
Company Location: Cranbury, NJ
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor
12 Month Price Targets:
High: $5.00
Mean: $3.00
Low: $2.00
News:
--HC Wainwright Adjusts Palatin Technologies' Price Target to $5 From $2, Keeps Buy Rating
MT NEWSWIRES 7:18 AM ET 11/24/2021
07:18 AM EST, 11/24/2021 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: www.mtnewswires.com)
Price: 0.3800, Change: +0.04, Percent Change: +10.34
MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
